US Patent

US12403173 — Micafungin compositions

Formulation · Assigned to Baxter Healthcare SA · Expires 2037-12-15 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable aqueous pharmaceutical composition of micafungin suitable for parenteral administration.

USPTO Abstract

An aqueous pharmaceutical composition suitable for parenteral administration and having enhanced storage stability includes between about 0.1 mg/mL and about 40 mg/mL micafungin; (ii) between about 0.1 mM and 400 mM buffering agent; and (iii) between about 0 mg/mL and about 500 mg/mL tonicity adjusting agent, wherein the pH of the composition is between about 3.0 and 7.0, for example, between about 3.5 and 7.0.

Drugs covered by this patent

Patent Metadata

Patent number
US12403173
Jurisdiction
US
Classification
Formulation
Expires
2037-12-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Baxter Healthcare SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.